CIM053-ADC / Cimeio Therap - LARVOL DELTA

Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases (ASH 2023) - "In summary, we developed a novel, highly potent tumor-selective therapy that spares a shielded hematopoietic system. Since CIM053-ADC targets the pan-hematopoietic marker CD45 this approach may not only be applicable to treat AML but most hematologic malignancies and possibly other diseases requiring HCT."

Hematological Malignancies • Oncology • Ophthalmology • PTPRC

Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers (Businesswire) - "Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and protected from the ADC via shielded hematopoietic stem cells (HSCs). The findings point to a novel and potentially universal approach to treating blood cancers....A group led by Dr. Lukas Jeker, and researchers at Cimeio have shown that acute myeloid leukemia (AML) cells can be eliminated using Cimeio’s proprietary CD45-targeting ADC. By transplanting engineered HSCs that are shielded from the CD45-directed therapy, the CD45 ADC was safely and effectively administered against the blood cancers."

Preclinical • Acute Myelogenous Leukemia

Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH (Businesswire) - "Cimeio Therapeutics...presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting....The first abstract...demonstrated the efficacy of Cimeio’s proprietary CD45 targeting ADC (CIM053-ADC) at depleting an aggressive AML cancer cell line in vivo, while the CD45 engineered HSCs were fully protected, engrafted and reconstituted the hematopoietic system in humanized mice. After just two doses of CIM053-ADC, all mice were cancer-free while the healthy hematopoietic cells were unaffected."

Preclinical • Acute Myelogenous Leukemia

Cimeio Therapeutics Announces Poster Presentations at ASH 2023 (Businesswire) - "Cimeio Therapeutics...announced the acceptance of two abstracts to be presented at the American Society of Hematology meeting....The first abstract is titled 'Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases.' These data demonstrate that CD45 antibody-drug conjugate (ADC) therapy effectively treated aggressive AML tumors in mouse models....The second abstract is titled 'Base Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression.' This abstract outlines the development of an edited epitope for CD33, which also resists depletion by paired CD33-directed immunotherapies while maintaining its expression."

Preclinical • Acute Myelogenous Leukemia